Aurin Biotech was founded in 2012 to advance the discoveries made by the McGeer and Associates Laboratory at the University of British Columbia (UBC). Dr. Patrick L. McGeer is Canadas most cited neuroscientist. Both he and his wife, Dr. Edith McGeer, are in the top 100 most cited neuroscientists in the world and their laboratory is well known for their work in neuroinflammation and neurodegenerative diseases, particularly Alzheimer disease. The McGeer laboratory first described the role of complement activation in the pathology of Alzheimer disease over 25 years ago. However, our team only recently discovered a collection of small molecules that are capable of inhibiting this ancient and powerful biochemical pathway. The painstaking discovery process involved screening thousands of pharmaceutical and chemical agents for the desired activity. Through subsequent experiments we determined that our drug candidates are orally effective and are able to cross the blood brain barrier. Based on these impressive results, our team founded Aurin Biotech to rapidly develop our lead drug candidate, AUR1107. AUR1107 has successfully passed compulsory pre-clinical safety studies and we are preparing for clinical trials to evaluate safety and efficacy in several conditions that are known to involve aberrant complement activation.